We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 20.52 | 2.27% | 924.00 | 855.00 | 963.00 | 943.77 | 891.30 | 900.00 | 1,066,981 | 01:00:00 |
From May 2022 to May 2024
By Michael Dabaie
The Food and Drug Administration said it granted to Regeneron Pharmaceuticals Inc. approval of Dupixent to treat inflammatory disorder chronic immune disorder eosinophilic esophagitis.
The FDA approval is for adults and pediatric patients 12 and older.
Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus. Common symptoms include difficulty swallowing, difficulty eating, and food getting stuck in the esophagus.
The FDA originally approved Dupixent in 2017. The drug is approved for moderate-to-severe atopic dermatitis and as an add-on maintenance treatment for certain types of moderate-to-severe asthma, as well as an add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyposis.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 20, 2022 15:27 ET (19:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
